http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20140131806-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0682 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2013-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_977feb26e5df0c1de9bea46bea74091d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9647c6dc32f270593f3abb956bf9f79f |
| publicationDate | 2014-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20140131806-A |
| titleOfInvention | Novel DHFR-deficient CHO cell line transfected by a vector which over-expresses Bcl-2 and Beclin-1 protein, and a method for preparation thereof |
| abstract | The present invention relates to a novel CHO host cell line transformed to simultaneously overexpress Bcl-2, an anticipated gene, and Beclin-1, a child-acting pathway gene, and lacking a dhfr (dihydrofolate reductase) gene and a method for producing the same. The transgenic CHO cell line of the present invention can inhibit cell proliferation due to overexpression of Bcl-2, which is an anti-prodrug protein, and induce cell death due to overexpression of Beclin-1, And it was confirmed that the induced pathway could inhibit cell death, and it was confirmed that cell death was more effectively inhibited than overexpression of Bcl-2, which is a conventional cell death suppression method, By confirming that the cell death induced by stress is inhibited, a therapeutic protein can be advantageously used for production. |
| priorityDate | 2013-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 552.